Revolution Medicines Reports Extended Survival in Pancreatic Cancer Trial
Revolution Medicines announced results from a Phase 3 study of its experimental drug daraxonrasib for advanced pancreatic adenocarcinoma. Patients treated with the drug had a median survival of 13.2 months, compared to 6.7 months for those on standard chemotherapy. The company plans to seek FDA approval based on these findings.
theprint.inRevolution Medicines reported results from a Phase 3 trial of its experimental drug daraxonrasib in patients with advanced pancreatic adenocarcinoma. 7 months. The company stated it intends to submit the data to the Food and Drug Administration for approval, though no specific timeline was provided.
Trial
Details and Expert Commentary Paul Oberstein, an investigator in the trial from NYU Langone’s Perlmutter Cancer Center, discussed the results on a biotech podcast.
He described the findings as potentially significant for pancreatic cancer treatment. Oberstein noted that pancreatic cancer is challenging to treat due to its aggressive nature and limited effective therapies.
“I do think it's a revolution," said Paul Oberstein of NYU Langone's Perlmutter Cancer Center.”
Background on Pancreatic Cancer
Pancreatic cancer has low survival rates, with current treatments offering limited benefits for advanced stages. The trial involved patients with advanced disease, comparing daraxonrasib to standard chemotherapy. Revolution Medicines indicated that approval, if granted, could occur quickly following submission.
Next
Steps The company plans to apply for Food and Drug Administration approval using the trial data.
Further details on the submission timeline were not announced. The results were presented as part of ongoing efforts to improve outcomes in pancreatic cancer.
Story Timeline
2 events- This week
Revolution Medicines announced Phase 3 trial results showing extended survival with daraxonrasib.
1 source@statnews - April 17, 2026
STAT spoke with Paul Oberstein about the trial on its biotech podcast.
1 source@statnews
Potential Impact
- 01
The drug could receive FDA approval, providing a new treatment option for pancreatic cancer patients.
- 02
Patients with advanced pancreatic cancer may access improved survival outcomes if approved.
- 03
Approval might lead to increased investment in similar targeted therapies for cancer.
- 04
Revolution Medicines' stock could see positive movement following the trial results.
Transparency Panel
Related Stories
Nbc NewsArtemis II Astronauts Share Experiences from Historic Lunar Flyby Mission
The four Artemis II astronauts held a press conference to discuss their 10-day mission around the moon, highlighting views of the lunar far side and a solar eclipse. They described emotional moments and the spacecraft's performance during reentry. The mission tested NASA's Orion…
The War ZoneU.S. Military Outlines Blockade Efforts Against Iranian-Linked Ships Amid Cease-Fire
U.S. military officials detailed ongoing naval blockade operations targeting Iranian-linked vessels globally, emphasizing warship capabilities and allied partnerships. Statements highlighted the degraded state of Iranian command and control, with warnings against cease-fire viola…
NASA Johnson Space Center / Wikimedia (Public domain)NASA's Artemis II Completes First Manned Moon Mission Since 1972, Sets Distance Record
NASA's Artemis II mission completed a flight around the moon and splashed down in the Pacific Ocean on Saturday. The mission marks the first manned moon mission since 1972 and set a record for the furthest humans have travelled into space at 252,756 miles (406,771km). Meanwhile,…